If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

Share Price is delayed by 15 minutes
Get Live Data
2.80    0.00 (0.00%)
Bid:
2.60
Ask:
3.00
Spread: 0.40 (15.385%)
Market Cap: £12.24m
RENX Live PriceLast checked at - London Stock Exchange

Intraday Renalytix Plc Share Chart

Director/PDMR Shareholding - Replacement

22 Jun 2021 13:25

RNS Number : 7366C
Renalytix AI PLC
22 June 2021
 

The following amendment(s) has been made to the ' Director/PDMR Dealing' announcement released on 22 June 2021 at 10:57 under RNS No 7062C.

 

The price of 113.5 pence per share was incorrect and has been amended to 1135 pence per share.

The Company was also informed of the sale 'yesterday'.

 

All other details remain unchanged.

 

The full amended text is shown below.

 

Renalytix AI plc 

 

("Renalytix" or the "Company")

 

Director/PDMR Dealing

 

The Company was informed that yesterday, Christopher Mills, a non-executive director and interim Chairman, completed the sale of 17,000 ordinary shares of 0.25 pence each ("Ordinary Shares") in the Company at a price of 1135 pence per share.

 

Following completion of the sale, Christopher Mills is interested in 9,180,501 Ordinary Shares representing 12.74% of the current issued share capital of the Company.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

 

Harwood Capital LLP and Harwood Capital Management (Gibraltar) Limited as investment manager to North Atlantic Smaller Companies Investment Trust plc and Oryx

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Christopher Mills, non-exec director and Interim Chair of the issuer and director of NASCIT and Oryx International Growth Fund Ltd

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Renalytix AI plc

b)

 

LEI

 

 

213800NTOH3FK3WER551

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of £0.0025 each

Identification code

GB00BYWL4Y04

 

 

b)

 

Nature of the transaction

 

 

Sale of shares

c)

Currency

GBP

d)

 

Price(s) and volume(s)

 

 

 

 

 

Price(s)

Volume(s)

 

 

£11.352941

17,000

 

 

 

 

 

e)

 

Aggregated information

- Aggregated volume

17,000

- Price

£192,999.99

f)

 

Date of the transaction

 

 

18 June 2021

g)

 

Place of the transaction

 

 

London Stock Exchange

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZZGZVZZFGMZM
Date   Source Headline
3rd Oct 20233:13 pmRNSIssue of Shares
3rd Oct 20237:00 amRNSMedicare prices kidneyintelX.dkd at $950
28th Sep 20237:00 amRNSRenalytix Reports Full Year Fiscal 2023 Results
25th Sep 20237:00 amRNSNotice of Results
22nd Sep 20237:00 amRNSPayer coverage expansion of KidneyIntelX
7th Sep 20237:00 amRNSAppointment of Chief Business Officer
21st Aug 20237:00 amRNSBusiness Update
3rd Aug 20239:10 amRNSRSU vesting for employees
3rd Aug 20237:00 amRNSFormation of Clinical Advisory Board
21st Jul 20237:00 amRNSVector Pharma Middle East Distribution Agreement
17th Jul 20231:43 pmRNSIssue of Shares - Replacement
17th Jul 20237:00 amRNSIssue of Shares
7th Jul 20237:00 amRNSKidneyIntelX evidence presented at ADA
6th Jul 20235:38 pmRNSGrant of Share Options
3rd Jul 20237:00 amRNSDirectorate Change
30th Jun 20237:00 amRNSFDA Approves KidneyIntelX.dkd™
15th Jun 20237:00 amRNSPresentation of Scientific Data
9th Jun 20237:00 amRNSFinancial Results for Q3 of Fiscal Year 2023
8th Jun 20233:30 pmRNSResult of General Meeting
5th Jun 20237:00 amRNSNotice of Q3 Results
25th May 20237:00 amRNSEVERSANA® partnership for KidneyIntelX
22nd May 20237:00 amRNSExpansion of insurance coverage for KidneyIntelX
11th May 20237:00 amRNSNotice of GM and Posting of Circular
19th Apr 20237:00 amRNSReal-World Evidence Shows KidneyIntelX™ Utility
12th Apr 20237:00 amRNSPositive Data Release at NKF Conference
30th Mar 20237:00 amRNSHalf-year Report
27th Mar 202312:50 pmRNSBusiness Update - Replacement
27th Mar 20237:00 amRNSBusiness Update
22nd Mar 20237:00 amRNSNotice of Results
21st Mar 20232:05 pmRNSSecond Price Monitoring Extn
21st Mar 20232:00 pmRNSPrice Monitoring Extension
21st Mar 20237:00 amRNSUpdate on FDA De Novo Authorization Process
13th Mar 20237:00 amRNSStatement re. Silicon Valley Bank
7th Mar 20237:00 amRNSIssue of Shares
10th Feb 20233:13 pmRNSHolding(s) in Company
10th Feb 20232:01 pmRNSDirector/PDMR Shareholding
9th Feb 20237:00 amRNSRENX to Participate in the BTIG MedTech Conference
8th Feb 20237:00 amRNSRenalytix announces a c.$20.3m private placement
26th Jan 20237:00 amRNSRenalytix and Partners Awarded $10 Million Grant
9th Jan 202311:05 amRNSSecond Price Monitoring Extn
9th Jan 202311:00 amRNSPrice Monitoring Extension
9th Jan 20237:00 amRNSCompletes Agreement with Veterans Administration
19th Dec 202212:01 pmRNSResult of AGM
1st Dec 20227:00 amRNSClinical utility study data: further highlights
30th Nov 20227:00 amRNSResults for First Quarter of Fiscal Year 2023
29th Nov 20227:00 amRNSPublication of new real world evidence
22nd Nov 20227:00 amRNSNotice of Q1 FY23 Results
10th Nov 20227:00 amRNSPublication of Annual Report 2022 & Notice of AGM
9th Nov 20224:35 pmRNSPrice Monitoring Extension
3rd Nov 20227:00 amRNSRENX to Present at Stifel Healthcare Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.